Elanco 10-Q Details Q3 Profit Swing: $18M Net Income, 56.9% Gross Margin, Debt Cut to $3.45B
ELAN sits 25% above its 52-week low of $19.4.
Summary
Elanco's Q3 10-Q backs up this morning's 8-K: net income of $18 million versus a $34 million loss a year ago, gross margin up to 56.9%, and debt down to $3.45 billion. The AHV deal closed for $241 million total consideration, mostly deferred and contingent.
Key Events · Earnings and Guidance · ELAN
-
Q3 Swings to $18M Profit
Revenue rose 11% to $1,265 million from $1,137 million, and net income was $18 million ($0.04 per diluted share) versus a $34 million loss a year earlier.
-
Gross Margin Jumps to 56.9%
Gross margin expanded from 53.4% to 56.9% on favorable pricing and product mix, lifting gross profit to $720 million from $607 million.
-
Debt Cut, Covenants in Compliance
Total debt fell to $3,449 million from $3,762 million at December 31, 2025, and the company stated it was in compliance with all debt covenants as of September 30, 2026.
-
AHV Deal Closed for $241M
The AHV International acquisition closed April 30, 2026 with $76 million cash at closing, $97 million deferred through 2030 (about $60 million due January 2027) and $68 million of contingent consideration.
Analysis · ELAN · Life Sciences
The headline numbers were already out this morning via the 8-K, but the 10-Q is where the quality of the quarter shows. Elanco swung from a $34 million loss to $18 million of net income as gross margin jumped to 56.9% from 53.4%, driven by pricing and a richer product mix (Zenrelia, Credelio Quattro, AdTab). Nine-month operating cash flow rose to $506 million from $452 million, and total debt fell to $3,449 million from $3,762 million at year-end, with all covenants in compliance. The AHV acquisition closed April 30 for $241 million total consideration, of which only $76 million was cash at closing — the rest is $97 million of deferred payments (about $60 million due January 2027) plus $68 million of contingent consideration. Legal risk is receding: the Barpar securities class action was dismissed with prejudice in March 2026 and is on appeal, and the Tevra and Safron matters have been resolved in Elanco's favor. Nothing here changes the thesis, but it confirms the margin and deleveraging story the market is paying for.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ELAN was trading at $24.32 on NYSE in the Life Sciences sector, with a market capitalization of approximately $11.8B. The 52-week trading range was $19.40 to $27.98. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.